Perinatal biologics supplier for medspas and dermatology in Worcester, MA

Cold-chain shipping for aesthetic practices

Cryopreserved Wharton's jelly formats ship overnight at -80 degrees Celsius on dry ice in validated shipping containers, which matters for medspas and dermatology offices that may not have a dedicated receiving process the way a hospital-based department does. A lyophilized exosome or Wharton's jelly format avoids that handling step entirely, since it is shelf-stable and stored at room temperature per the insert that accompanies the lot. Either way, the order should be logged against the physician's account on arrival.

Who can open an account

Ordering access is restricted to accounts verified against an NPI number belonging to a licensed physician, consistent with selling only to licensed clinics, physician-supervised medspas and physicians directly. A medspa's supervising physician, rather than an aesthetician or front-desk staff, is the person whose NPI anchors the account and who is responsible for how any product is used.

• Supervising physician's NPI number
• Practice or medspa business information
• Confirmation of physician supervision for medspa accounts

What a dermatology or medspa vendor review tends to cover

A dermatology practice or medspa evaluating a new biologics source generally wants to see the supplier's donor screening approach, confirmation that each lot passed third-party sterility testing before release from quarantine, and whether a documentation-focused conversation is available. None of that substitutes for the practice's own review of whether a specific intended use fits its regulatory posture.

Documentation and state-level verification

Massachusetts medical directors and their counsel are responsible for determining how a product and its intended use are classified for their practice, and should direct specific questions to the Massachusetts medical board rather than to a distributor. FDA has stated there are no FDA-approved exosome products, and Wharton's jelly allografts are offered under the supplier's HCT/P framework; whether either fits a given intended use is a determination for the clinic and its counsel, not Precision Biologics.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.